Compare · FLGC vs MRK
FLGC vs MRK
Side-by-side comparison of Flora Growth Corp. (FLGC) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLGC and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $283.78B, about 3022.0x FLGC ($93.9M).
- Over the past year, FLGC is down 68.8% and MRK is up 41.9% - MRK leads by 110.6 points.
- MRK has hit the wire 23 times in the past 4 weeks while FLGC has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 3 for FLGC).
- Company
- Flora Growth Corp.
- Merck & Company Inc.
- Price
- $8.61-24.24%
- $114.90-3.47%
- Market cap
- $93.9M
- $283.78B
- 1M return
- +17.46%
- +1.31%
- 1Y return
- -68.77%
- +41.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 23
- Recent ratings
- 3
- 25
Flora Growth Corp.
Flora Growth Corp., a cannabis company, cultivates, processes, and supplies cannabis products to pharmacies, medical clinics, and cosmetic companies worldwide. It cultivates, processes, and supplies medicinal-grade cannabis oil, and cannabis oil extracts and related products; manufactures and sells skincare and beauty products, such as gel cleanser, eye cream, moisturizer, and hydrating mask; manufactures dermo cosmetic products; and develops and sells pharmaceutical and over-the-counter products, including dietary supplements, phytotherapeutic and nutraceutical products, supplements, and related products. It also manufactures and sells hemp textiles products focuses on servicing the hospitality, medical, and clothing industries on a B2B basis; designs, produces, and supplies juices, chocolate, and chocolate related products to wholesale distributors, pharmacies, supermarkets, and online distributors; and offers and wellness products. The company's brand includes Mambe, Mind Naturals, Almost Virgin, Flora Lab, and Stardog Loungewear. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest FLGC
- Flora Growth Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Flora Growth Corp.
- SEC Form FWP filed by Flora Growth Corp.
- SEC Form 424B3 filed by Flora Growth Corp.
- Flora Growth Corp. Announces Name Change to ZeroStack Corp., Furthering Its Strategy as an AI-Focused Asset Management Company
- SEC Form EFFECT filed by Flora Growth Corp.
- DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
- SEC Form 3 filed by new insider Zeifman Laurence
- SEC Form S-3 filed by Flora Growth Corp.
- Flora Growth Corp. filed SEC Form 8-K: Leadership Update
Latest MRK
- Merck Animal Health to Acquire TARGAN
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul